Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glycopyrrolate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Level A | EXPERIMENTAL | The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to |
| Dose Level B | EXPERIMENTAL | The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to |
| Dose Level C | EXPERIMENTAL | The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to |
| Dose Level D | PLACEBO_COMPARATOR | The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to |
| Name | Type | Description |
|---|---|---|
| Glycopyrrolate (85 μg) | DRUG | Administered by a standard jet nebulizer, twice daily for 7 consecutive days |
| Glycopyrrolate (42.5 μg) | DRUG | Administered by a standard jet nebulizer, twice daily for 7 consecutive days |
| Glycopyrrolate (14 μg) | DRUG | Administered by a standard jet nebulizer, twice daily for 7 consecutive days |
| Placebo | DRUG | Administered by a standard jet nebulizer, twice daily for 7 consecutive days |
Inclusion Criteria: * Males are eligible to participate if they agree to use contraception from Screening and throughout the study and for at least 30 days after the last dose of blinded study medication. * Females are eligible to participate if they are not pregnant, not breastfeeding, and ≥ 1 of ...
Glycopyrrolate is an investigational small molecule being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is administered as an inhalation solution. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Glycopyrrolate is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Chronic Obstructive Pulmonary Disease.
Glycopyrrolate is in Phase 2 clinical development. A Phase IIb study of the drug has been completed in patients with Chronic Obstructive Pulmonary Disease. The drug is investigational and has not received approval from the U.S. Food and Drug Administration or other regulatory bodies.
Glycopyrrolate has one completed clinical trial registered under the identifier NCT06545500. This was a Phase IIb study of Glycopyrrolate Inhalation Solution over one week in subjects with Chronic Obstructive Pulmonary Disease. The trial enrolled 46 participants in the United States and was randomized, double-blind, and placebo-controlled.
Glycopyrrolate is a specific drug being developed by Merck & Company, Inc. for Chronic Obstructive Pulmonary Disease. It is not identified as being the same as any other named medication in the available information. Its mechanism of action and relationship to other COPD treatments have not been specified.